University of Ioannina
Αλληλεπίδραση αιμοπεταλίων με καρκινικά κύτταρα: ρόλος στις θρομβωτικές επιπλοκές του καρκίνου και την καρκινογένεση
Abstract
dc:descriptionIntroduction: Platelet-tumor cell interaction plays an important role in both carcinogenesis and thrombotic complications in cancer patients. The aim of this PhD thesis is to investigate the mechanisms of platelet-tumor cell interaction, to highlight those that play important roles in the interaction and activation of these cells, and finally to present new synthetic Nilotinib analogues that express strong antitumor activity. Methods: In this context, twelve new Nilotinib analogues, a BCR-ABL tyrosine kinase inhibitor used to treat chronic myelogenous leukemia, have been designed and synthesized by the Organic Chemistry laboratory, and their antiplatelet and antitumor properties were studied for the first time. Initially, Nilotinib and all the analogues were studied by light transmittance aggregometry to investigate their ability to inhibit platelet aggregation, in vitro, after activation with AA, ADP, TRAP-6 and U-46619. At the same time, we studied the interaction of these analogues with antiplatelet agents, such as Ticagrelor and Vorapaxar. Furthermore, the analogues were studied by impedance aggregometry in whole blood, in order to evaluate their antiplatelet activity, in more reassembling conditions of human blood, as the ones in in vivo experiments, as well as by flow cytometry, in order to investigate their activity on the membrane expression of P-selectin and PAC-1, after activation with AA. Finally, in order to delve more into their mechanism of action, we investigated by ELISA, their effect on the thromboxane synthesis pathway, after platelet activation with AA.We continued our study to evaluate their cytostatic and antimetastatic properties. First, we studied by flow cytometry, the effect of Nilotinib and its analogues on the cell cycle of HepG2 cells. The same study was performed after the incubation of HepG2 cells with lysine acetylsalicylate or platelets. Moreover, the analogues, as well as lysine acetylsalicylate, were examined for their apoptotic activity by flow cytometry. The apoptotic assay was also performed in healthy endothelial cells HUVECs, in order to evaluate their safety. Next, we investigated by Western Blot, the effect of Nilotinib and its analogues on the expression of two adhesion proteins, E-cadherin and N-cadherin. We continued by studying the effect of the analogues, as well as platelets, on the migration of HepG2 cells using the Boyden chamber assay. Finally, we investigated by ELISA, the effect of the analogues on the phosphorylation of Src kinase, in HepG2 cell lysates. Results: The analogues-1, -2, and -3 exhibited significantly stronger inhibitory effect against AA-induced platelet aggregation, compared to Nilotinib, while none of the analogues inhibited platelet aggregation when ADP, TRAP-6 or U-46619 were used as agonists. None of the analogues in combination with Ticagrelor demonstrated any interaction, whereas, all three analogues in combination with Vorapaxar revealed a synergistic effect, causing a significant increase in inhibition of platelet aggregation. In whole blood, only the analogue-3 was able to induce strong antiplatelet activity at a low concentration. Analogues-1, -2 and -3 strongly inhibited the membrane expression of P-selectin and PAC-1, even at low concentrations, while also exhibiting significant inhibition of TxB2 synthesis, compared to Nilotinib. Regarding HepG2 cells, Nilotinib caused a slight increase in the percentage of M1 phase cells, while conversely analogues-1, -2 and -3 caused a decrease in M1 phase cells and a significant increase in M3 phase cells. The analogues, lysine acetylsalicylate, as well as platelets, did not significantly change the distribution of cancer cells in the cell cycle. Nilotinib and analogues-1 and -3 demonstrated a significant decrease in viable cells, but only the analogue-3 exhibited strong apoptotic activity, while lysine acetylsalicylate did not affect the percentage of apoptotic cells at all. None of the analogues induced apoptosis in healthy endothelial cells HUVECs. Also, a large decrease in E-cadherin expression was observed by analogues-1 and -3, while analogues-2 and -3 caused a greater decrease in N-cadherin expression, compared to Nilotinib. All three analogues caused a significant reduction in metastatic HepG2 cells, whereas platelets failed to differentiate their migration rate. None of the three analogues affected the Src kinase, since they did not cause any significant effect in its phosphorylation. Conclusions: Analogues-1, -2 and -3, exhibited similar potent antiplatelet activity. Regarding their antitumor properties, analogue-1 and -3 appeared to have similar activity in most assays performed, with the analogue-3 revealing the strongest apoptotic activity in HepG2 cells. We therefore observed that the structural alterations made to the model compound of Nilotinib, enhanced both its antiplatelet and cytostatic properties. The results so far, indicate that there is a significant potential for the development of new synthetic TKIs, with potent antiplatelet activity and enhanced cytostatic properties, for the treatment of cancer and at the same time the effective prevention of CAT.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Pechlivani, Louiza
- Πεχλιβάνη, Λουίζα
Subjects
dc:subject × 22- Αιμοπετάλια
- Αναστολείς τυροσινικής κινάσης
- Θρόμβωση σχετιζόμενη με τον καρκίνο
- Καρκινικά κύτταρα
- Platelets
- Tyrosine kinase inhibitors
- Cancer-associated thrombosis
- Cancer cells
- Bcr-Abl
- Nilotinib analogues
- Χημεία
- Φυσικές Επιστήμες
- Χημεία, διεπιστημονική προσέγγιση
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ιατρική βιοχημεία
- Chemical Sciences
- Natural Sciences
- Chemistry, interdisciplinary
- Basic Medicine
- Medical and Health Sciences
- Medical Biochemistry
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56314